MPIA
MNPR icon

Mountain Pacific Investment Advisers’s Monopar Therapeutics MNPR Stock Holding History

Mountain Pacific Investment Advisers’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,100
Closed -$398K – 143
2025
Q4 		$398K Buy
+6,100
New +$498K 0.06% 116

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Mountain Pacific Investment Advisers's MNPR Position: Q1 2026 in Review

Mountain Pacific Investment Advisers sold out of Monopar Therapeutics (MNPR) in Q1 2026, closing a stake of 6,100 shares — an estimated $398K sold.

Mountain Pacific Investment Advisers first reported a position in MNPR in Q4 2025 and held it in 1 quarter. The position peaked at $398K in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Mountain Pacific Investment Advisers reported no remaining Monopar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Mountain Pacific Investment Advisers sold 6,100 Monopar Therapeutics shares in Q1 2026, an estimated $398K.
  • Mountain Pacific Investment Advisers first reported a position in Monopar Therapeutics in Q4 2025 and held it in 1 quarter.
  • Mountain Pacific Investment Advisers's Monopar Therapeutics position peaked at $398K in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Mountain Pacific Investment Advisers's 13F filing for Q1 2026, filed 16 Apr 2026.